View Cart (0 items)
Pharmaceutical

Pfizer signs agreement with MIT to open research center

September 08, 2011
/ Print / Reprints /
| Share More
/ Text Size+

NEW YORK — Pfizer Inc. has entered into a 10-year lease agreement with the Massachusetts Institute of Technology (MIT) for more than 180,000 square feet in a new building under development in Cambridge, Mass., that will be the future location of Pfizer’s Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units, according to a press release.

The relocation of the two Research Units will substantially boost Pfizer’s footprint in Cambridge, making it the second largest biopharmaceutical company in Massachusetts in terms of jobs.

“We were very deliberate in our choice to move to Cambridge, Mass., as a key part of our R&D strategy. By expanding our presence in one of the world’s great centers of scientific and medical innovation, we will provide the best environment for our researchers to invent the next generation of medicines in areas of greatest need, such as Alzheimer’s disease, schizophrenia, diabetes and cardiovascular disease,” said Rod MacKenzie, senior vice president and head of PharmaTherapeutics Research & Development.
You must login or register in order to post a comment.